Log in or register to see all Alerts
New HTA Decisions in Scotland
June 2020
Drug name
TECENTRIQ® (atezolizumab)
Decision date
Therapeutic area
Therapeutic sub area
Lung cancer
Not recommended
In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with epidermal growth factor receptor (EDFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC, atezolizumab in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.
Decision Detail
Following a full submission considered under the end of life medicine process, atezolizumab (TECENTRIQ®) is not recommended for us within NHS Scotland.
In a phase III study (IMpower150), the addition of atezolizumab to bevacizumab, carboplatin and paclitaxel was associated with an increase in median progression-free survival in patients with metastatic non-squamous NSCLC. The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC. This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.